A Large-Scale, Multicentered Trial Evaluating the Sensitivity and Specificity of Digital PCR Versus ARMS-PCR for Detecting Ctdna-Based EGFR P.t790m in Non-Small-cell Lung Cancer Patients.
Jiachen Xu,Wei Wu,Chunyan Wu,Yong Mao,Xiaowei Qi,Lin Guo,Renquan Lu,Shuhong Xie,Jiatao Lou,Yu Zhang,Yiyan Ding,Zijian Guo,Li Zhang,Naixin Liang,Peng Chen,Cuicui Zhang,Min Tao,Zhengyuan Yu,Hua Geng,Meilin Xu,Meiqi Shi,Li Wang,Wei Guo,Jun Zhao,Jianjie Li,Lixia Shi,Yan Zhang,Zhonghua Qin,Jun Chen,Jinghao Liu,Jing Ren,Zhenlin Yang,Xin Pan,Zhaoqing Lv,Hao Dong,Jie Zhang,Jiajia Ou,Zhaoliang Li,Kavanaugh Kaji,Yan Wang,Jie Wang,Zhijie Wang
DOI: https://doi.org/10.21037/tlcr-21-564
2021-01-01
Translational Lung Cancer Research
Abstract:BACKGROUND:Developing liquid biopsy technology with higher sensitivity and specificity especially for low-frequency mutations remains crucial. This study demonstrated superior performance of the newly developed digital PCR (dPCR) kit for ctDNA-based EGFR p.T790M detection in metastatic non-small-cell lung cancer (NSCLC) against ARMS-PCR.METHODS:This large-scale, multi-centered diagnostic study recruited 1,045 patients including 1,029 patients diagnosed with advanced NSCLC and 16 patients with specific samples between April 1st 2018 and November 30th 2019. EGFR p.T790M in plasma samples from mNSCLC patients were tested using dPCR with ADx-ARMS PCR and Cobas® EGFR Mutation Test V2 as comparator assays to confirm cut-off value for dPCR and evaluate its performance against ARMS-PCR-based assays. Efficacy was evaluated for patients with EGFR p.T790M detected by dPCR or ARMS-PCR, who underwent Osimertinib treatment.RESULTS:The sensitivity, specificity, and concordance of dPCR against ADx-ARMS PCR was 98.15%, 88.66% and 90.16%, respectively for 1,026 plasma samples. Additional 9.26% patients were detected positive by dPCR. The majority of those samples had a mutation allele frequency between 0.1% and 1%. In 45 paired tissue and plasma samples, the sensitivity improved from 30.77% to 53.85% by dPCR with the specificity over 90%. The response of Osimertinib in 74 EGFR p.T790M-positive patients detected by dPCR, including 26 determined as negative by ARMS-PCR, were evaluated to have an ORR of 44.59% and a DCR of 90.54%.CONCLUSIONS:dPCR is a sensitive and accurate tool for ctDNA-based EGFR p.T790M detection due to its significantly improved sensitivity without compromising specificity, and dPCR is equivalent to ARMS-PCR as a companion diagnostic tool while benefiting more patients under Osimertinib treatment.TRIAL REGISTRATION:Chinese Clinical Trial Registry identifier: ChiCTR2100043147.